RxDoctor Payments Data

Adejoke Aina-Babalola, MD

Internal Medicine · Brentwood, TNNPI 1669556148

Payments from drug & device makers

$3,961in general payments, 2019–2025

Across 196 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$1K
  • AbbVie$332
  • Novo Nordisk$299
  • AstraZeneca$267
  • Lilly USA, LLC$229
  • Paratek Pharmaceuticals, Inc.$188
  • plus $1K from 35 others

What the payments were for

  • Food & beverage$3,961100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,961 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$44,295
Medicare patients
115
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$54,285
OzempicSemaglutide32$47,797
FarxigaDapagliflozin Propanediol52$47,582
RybelsusSemaglutide19$32,149
CreonLipase/Protease/Amylase23$24,248
LinzessLinaclotide22$20,382
EliquisApixaban22$13,350
JardianceEmpagliflozin20$12,120
Famotidine41$3,104
Olmesartan Medoxomil40$2,296
Lidocaine27$2,283
Atorvastatin Calcium165$2,140
Albuterol Sulfate HfaAlbuterol Sulfate48$1,656
Fluticasone Propionate54$1,531
Colestipol Hcl12$1,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$299$79,94651 claims
Lilly USA, LLCMounjaro$229$54,28536 claims
AstraZenecaFarxiga$267$47,58252 claims
AbbVieCreon, Linzess$332$44,63045 claims
PfizerEliquis$125$13,35022 claims
Boehringer IngelheimJardiance$26$12,12020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Brentwood

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →